Ad
related to: pfizer, drugmaker
Search results
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Zacks via Yahoo Finance· 5 days agoPfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to...
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Reuters via AOL· 2 days agoPfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the...
Pfizer Study Shows Lorbrena Reduces Chances of Lung Cancer Getting Worse
Morningstar· 2 days agoPfizer said a majority of patients in a study of its lung cancer treatment Lorbrena remained alive after five years without the disease worsening. The drugmaker< ...
Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer...
Benzinga· 2 days agoOn Friday, Pfizer Inc PFE released longer-term follow-up results from the Phase 3 CROWN trial...
US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label
Reuters· 2 days ago, opens new tab respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving...
EU regulator recommends use of Pfizer's gene therapy for rare bleeding disorder
Reuters· 2 days agoThe European Medicines Agency has recommended the use of Pfizer's gene therapy for a rare bleeding...
Novartis leukemia drug more effective than older treatments in trial
Reuters via Yahoo News· 2 days agoSwiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a...
Moderna wins FDA approval for RSV vaccine
BioPharma Dive via Yahoo Finance· 2 days agoThe OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.
3 Dividend Stocks to Double Up on Right Now
Motley Fool via Yahoo Finance· 3 days agoThe biopharma company has also used a lot of the cash made when COVID-19 was a more serious concern to gobble up smaller drugmakers. Since 2022, Pfizer...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 2 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...
